|
業務類別
|
Biotechnology |
|
業務概覽
|
Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate forautoimmune diseases. |
| 公司地址
| 40 Guest Street, Boston, MA, USA, 02135 |
| 電話號碼
| +1 617 949-2680 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.cuebiopharma.com |
| 員工數量
| 29 |
| Dr. Daniel G. Baker, M.D.,PhD |
Interim Chief Development Officer |
-- |
16/03/2026 |
| Dr. Shao-Lee Lin, M.D.,PhD |
Director, President and Chief Executive Officer |
-- |
01/05/2026 |
| Mr. Michael Meluzio |
Vice President and Principal Accounting Officer |
-- |
02/06/2026 |
| Mr. Colin G. Sandercock |
Senior Vice President, Intellectual Property |
美元 448.65K |
02/06/2026 |
| Ms. Sumita Ray, J.D. |
Chief Legal and Compliance Officer and Corporate Secretary |
-- |
02/06/2026 |
|
|
| Mr. Daniel A. Camardo, M.B.A. |
Independent Director |
02/06/2026 |
| Ms. Viola Mong Meehan |
Independent Director |
02/06/2026 |
| Dr. Pasha Sarraf, M.D.,PhD |
Chairman of the Board |
16/03/2026 |
| Dr. Shao-Lee Lin, M.D.,PhD |
Director, President and Chief Executive Officer |
01/05/2026 |
| Ms. Pamela D. Garzone |
Independent Director |
16/03/2026 |
|
|
|
|
